These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11855791)

  • 1. Urinary trypsin inhibitor levels in the urine of patients with haematological malignancies.
    Takubo T; Kumura T; Nakamae H; Aoyama Y; Koh KR; Ohta K; Yamane T; Hino M; Kanashima H; Kamitani T; Ohta T; Kuwajima S; Tatsumi N
    Haematologia (Budap); 2001; 31(3):267-72. PubMed ID: 11855791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination assay of urinary free L-fucose and trypsin inhibitor may be useful indicators of disease activity in patients with hematologic malignancies.
    Takubo T; Aoyama Y; Nakamae H; Tanaka K; Ohta K; Yamane T; Hino M
    Leuk Lymphoma; 2002 Nov; 43(11):2241-3. PubMed ID: 12533057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Human urinary trypsin inhibitor].
    Takubo T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():771-3. PubMed ID: 16149637
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunochemical studies of human urinary trypsin inhibitor.
    Maehara S; Sumi H; Toki N
    Enzyme; 1981; 26(3):122-8. PubMed ID: 6166469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Incidence of haematological malignancies in adults in Szabolcs-Szatmár-Bereg county, Hungary, between 1983 and 2012. Analysis of data from a thirty-year period].
    Jakó J; Szerafin L; Nagy P
    Orv Hetil; 2013 Nov; 154(47):1858-64. PubMed ID: 24240522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Patient Remote Intervention and Symptom Management System (PRISMS) - a Telehealth- mediated intervention enabling real-time monitoring of chemotherapy side-effects in patients with haematological malignancies: study protocol for a randomised controlled trial.
    Breen S; Ritchie D; Schofield P; Hsueh YS; Gough K; Santamaria N; Kamateros R; Maguire R; Kearney N; Aranda S
    Trials; 2015 Oct; 16():472. PubMed ID: 26481873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detectable concentrations of urinary trypsin inhibitor in cerebrospinal fluid.
    Iwama H; Ohmori S; Tsutsumi T
    J Neurosurg Anesthesiol; 2000 Jan; 12(1):29-32. PubMed ID: 10636617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.
    Ganai SA
    J Chemother; 2016 Aug; 28(4):247-54. PubMed ID: 27121910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemical model for the agglutination reaction of FR antigens in a new latex photometric immunoassay with near infrared turbidimetry.
    Sudo T; Tsutsui S; Ito M; Morita S; Sawai M
    Kitasato Arch Exp Med; 1980 Jun; 53(1-2):55-68. PubMed ID: 7277958
    [No Abstract]   [Full Text] [Related]  

  • 10. What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.
    Williams AM; Zent CS; Janelsins MC
    Br J Haematol; 2016 Sep; 174(6):835-46. PubMed ID: 27391367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004].
    Troussard X; Duchenet V; Cornet E; Mouchel D; Malet M; Collignon A
    Rev Epidemiol Sante Publique; 2009 Jun; 57(3):151-8. PubMed ID: 19375876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urinary trypsin inhibitor as an acute phase reactant].
    Kuwajima S; Noda T; Izumi Y; Kitao H; Naka K; Okuda K
    Rinsho Byori; 1992 Jul; 40(7):751-5. PubMed ID: 1507494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
    Takai S; Tsurumi H; Ando K; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Takahashi T; Oyama M; Onishi H; Tomita E; Takami T; Imawari M; Moriwaki H
    Eur J Haematol; 2005 Feb; 74(2):158-65. PubMed ID: 15654908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological evaluation of urinary trypsin inhibitors in blood and urine: role of N- & O-linked glycoproteins.
    Pugia MJ; Jortani SA; Basu M; Sommer R; Kuo HH; Murphy S; Williamson D; Vranish J; Boyle PJ; Budzinski D; Valdes R; Basu SC
    Glycoconj J; 2007 Jan; 24(1):5-15. PubMed ID: 17115277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological activation of the p53 pathway in haematological malignancies.
    Saha MN; Micallef J; Qiu L; Chang H
    J Clin Pathol; 2010 Mar; 63(3):204-9. PubMed ID: 19955555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sensitive kinetic latex agglutination immunoassay adapted to centrifugal analysis.
    Lentrichia BB; Yeung KK
    J Immunol Methods; 1986 May; 89(2):257-63. PubMed ID: 3701076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.
    Sant M; Minicozzi P; Mounier M; Anderson LA; Brenner H; Holleczek B; Marcos-Gragera R; Maynadié M; Monnereau A; Osca-Gelis G; Visser O; De Angelis R;
    Lancet Oncol; 2014 Aug; 15(9):931-42. PubMed ID: 25030467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an ELISA test for determination of the urinary trypsin inhibitor: analytical performance and applications.
    D'Ercole S; Priori AM; Pucciarelli S; Fioretti E; Tacconi R; Angeletti M; Eleuteri AM; Pucci E
    J Immunoassay Immunochem; 2005; 26(1):43-56. PubMed ID: 15754804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute interstitial pneumonitis during chemotherapy for haematological malignancy.
    Nakase K; Tsuji K; Nagaya S; Tamaki S; Tanigawa M; Ikeda T; Miyanishi E; Shiku H
    Eur J Cancer Care (Engl); 2005 Sep; 14(4):336-41. PubMed ID: 16098118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunoglobulin quantitation by latex agglutination immunoassay--new sample treatment to reduce differences in measured values by turbidimetric immunoassay].
    Kubota N
    Rinsho Byori; 2010 Apr; 58(4):387-92. PubMed ID: 20496767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.